Status:
UNKNOWN
Uterine Cavity Assessment and Endometrial Gene Expression in Tamoxifen Treated Breast Cancer Patients
Lead Sponsor:
Sheba Medical Center
Conditions:
Endometrial Receptivity Post Tamoxifen Exposure
Eligibility:
FEMALE
18-45 years
Brief Summary
The aim of this multi-center study is to assess the effects of Tamoxifen on the uterine cavity and endometrial abnormalities in young premenopausal women diagnosed with breast cancer. The research co...
Detailed Description
Breast cancer is the most prevalent malignancy amongst women and approximately 13% of newly diagnosed breast cancer patients are diagnosed between the ages 20-34 \[1\]. At this age group women are at ...
Eligibility Criteria
Inclusion
- Breast cancer patients who are:
- \< 45 years
- premenopausal
- Had no previous uterine operations (previous D\&C is allowed)
- Currently receiving or having received Tamoxifen for at least 1 year.
Exclusion
- None
Key Trial Info
Start Date :
January 1 2015
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
February 1 2017
Estimated Enrollment :
120 Patients enrolled
Trial Details
Trial ID
NCT02311647
Start Date
January 1 2015
End Date
February 1 2017
Last Update
December 23 2014
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
The Chaim Sheba Medical Center
Tel Litwinsky, Israel, 52621